Press release
Inflammation and Pain Post Cataract Surgery Market Trends, Treatments and Forecast
Inflammation and Pain Post Cataract Surgery
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70915
Traditionally, topical corticosteroids and NSAIDs (non-steroidal anti-inflammatory drugs) have been the mainstay of treatment. Recently, innovation has introduced sustained-release intraocular implants, drug-eluting devices, and combination therapies, significantly improving patient compliance. With the global rise in cataract surgeries, the market for managing post-surgical inflammation and pain is set to expand rapidly.
By 2034, the Inflammation and Pain Post-Cataract Surgery Market is expected to reach USD 6.7 billion, up from USD 3.1 billion in 2024, growing at a CAGR of 8.2%.
Market Overview
• Market Size 2024: USD 3.1 billion
• Forecast 2034: USD 6.7 billion
• CAGR (2024-2034): ~8.2%
Key Growth Drivers:
• Growing geriatric population prone to cataracts.
• Advances in drug delivery technologies (e.g., intraocular implants, injectables).
• Increasing global access to cataract surgeries in emerging economies.
• Rising awareness of post-operative care compliance.
Challenges:
• Side effects of long-term corticosteroid use (elevated intraocular pressure, glaucoma risk).
• Patient non-compliance with eye drop regimens.
• High cost of advanced drug-delivery implants.
Leading Players:
Novartis AG (Alcon), Bausch + Lomb, Allergan (AbbVie), Ocular Therapeutix, EyePoint Pharmaceuticals, Sun Pharmaceutical, Johnson & Johnson Vision, Santen Pharmaceutical, Omeros Corporation, and Lupin Limited.
Segmentation Analysis
By Product
• Corticosteroids (Topical Drops, Injectable, Implants)
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Combination Drugs (Steroid + NSAID)
• Sustained-Release Implants/Drug-Eluting Devices
• Others (Adjunctive Therapies)
By Platform
• Topical Eye Drops
• Injectable Therapies
• Sustained-Release Implants
• Drug-Eluting Contact Lenses
By Technology
• Nanoparticle Drug Delivery
• Sustained-Release Polymer Implants
• Biodegradable Implants
• Micro-needle & Ocular Injection Systems
By End Use
• Hospitals
• Ambulatory Surgical Centers
• Ophthalmology Clinics
• Retail & Online Pharmacies
By Application
• Pain Relief
• Inflammation Control
• Infection Prevention (Adjunctive Use)
Segmentation Summary:
Corticosteroids and NSAIDs dominate the market today, but the fastest growth is expected in sustained-release drug delivery implants, reducing the burden of daily eye drops and ensuring better patient compliance.
Explore Full Report here: https://exactitudeconsultancy.com/reports/70915/inflammation-and-pain-post-cataract-surgery-market
Regional Analysis
North America
• Largest market (~42% share in 2024).
• Strong presence of global ophthalmic drug leaders and FDA-approved sustained-release therapies.
• High cataract surgery volume due to aging population.
Europe
• Second-largest market.
• Widespread adoption of topical NSAIDs and combination therapies.
• Germany, UK, and France leading in advanced ophthalmic implants.
Asia-Pacific
• Fastest-growing region (CAGR ~10%).
• Large cataract surgery base due to government-backed vision programs (India, China, Japan).
• Growing accessibility of cost-effective generic ophthalmic drugs.
Middle East & Africa
• Rising cataract treatment programs supported by NGOs and healthcare initiatives.
• Limited penetration of advanced implants due to cost barriers.
Latin America
• Increasing cataract surgeries in Brazil and Mexico.
• Strong growth in affordable generics and corticosteroid eye drops.
Regional Summary:
North America and Europe dominate revenues, but Asia-Pacific is emerging as the key growth hub with large patient populations, rising healthcare access, and high adoption of generic ophthalmic drugs.
Market Dynamics
Growth Drivers
• Aging population driving demand for cataract surgeries.
• Technological innovation in drug delivery implants and ocular therapeutics.
• Expanding healthcare access in emerging economies.
• Regulatory approvals for long-acting ocular therapies.
Key Challenges
• Risk of steroid-related side effects.
• Compliance challenges in long-term drop regimens.
• Limited affordability of premium sustained-release implants.
Latest Trends
• Surge in sustained-release drug delivery systems (e.g., Dextenza by Ocular Therapeutix).
• Development of nanotechnology-based ocular drugs for precise delivery.
• Expansion of generic NSAID and corticosteroid formulations in Asia and Latin America.
• Use of teleophthalmology platforms to monitor post-surgery recovery remotely.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70915
Competitor Analysis
Major Players:
1. Novartis AG (Alcon)
2. Bausch + Lomb
3. Allergan (AbbVie)
4. Ocular Therapeutix
5. EyePoint Pharmaceuticals
6. Sun Pharmaceutical
7. Johnson & Johnson Vision
8. Santen Pharmaceutical
9. Omeros Corporation
10. Lupin Limited
Competitive Summary:
The market is moderately consolidated, with Novartis, Bausch + Lomb, and AbbVie holding strong shares in corticosteroid and NSAID segments. Ocular Therapeutix and EyePoint Pharmaceuticals are disrupting the market with sustained-release ocular implants that reduce patient burden and improve compliance.
Conclusion
The Inflammation and Pain Post-Cataract Surgery Market is poised for steady growth, driven by rising cataract surgery volumes, expanding aging populations, and innovation in drug delivery. While traditional corticosteroids and NSAIDs will continue to dominate, sustained-release implants and nanotechnology-driven solutions are shaping the future of post-surgical care.
Key Takeaways:
• Market to grow from USD 3.1 billion in 2024 to USD 6.7 billion by 2034, CAGR 8.2%.
• Corticosteroids and NSAIDs lead, but sustained-release implants show fastest growth.
• North America and Europe dominate, while Asia-Pacific is the fastest-growing region.
• Technological advances in ocular drug delivery will transform post-cataract surgery recovery.
By 2034, post-cataract inflammation and pain management is expected to transition from daily eye drop regimens to sustained, long-acting therapeutic solutions, significantly improving patient quality of life and recovery outcomes.
This report is also available in the following languages : Japanese (白内障手術後の炎症と疼痛市場), Korean (백내장 수술 후 염증 및 통증 시장), Chinese (白内障术后炎症和疼痛市场), French (Marché de l'inflammation et de la douleur après une chirurgie de la cataracte), German (Markt für Entzündungen und Schmerzen nach Kataraktoperationen), and Italian (Mercato dell'infiammazione e del dolore post-intervento di cataratta), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/70915/inflammation-and-pain-post-cataract-surgery-market#request-a-sample
Our More Reports:
Sickle Cell Disease Market
https://exactitudeconsultancy.com/reports/71292/sickle-cell-disease-market
Thrombocytopenia Market
https://exactitudeconsultancy.com/reports/71293/thrombocytopenia-market
Thrombotic Thrombocytopenic Purpura Market
https://exactitudeconsultancy.com/reports/71294/thrombotic-thrombocytopenic-purpura-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Inflammation and Pain Post Cataract Surgery Market Trends, Treatments and Forecast here
News-ID: 4147898 • Views: …
More Releases from Exactitude Consultancy
PD-L1 Metastatic Non-Small Cell Lung Cancer Market is expected to double by 2034 …
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, with metastatic NSCLC being the most advanced and life-threatening form. Over the past decade, the introduction of PD-1/PD-L1 checkpoint inhibitors has revolutionized treatment paradigms, significantly improving survival outcomes for many patients. Drugs targeting PD-L1 expression, including atezolizumab, durvalumab, and avelumab, are now central to first-line and subsequent therapy settings.
Download Full PDF Sample Copy of Market Report…
Papilloma Market is Expected to Reach USD 2.7 Billion by 2034
Papillomas are benign epithelial tumors often associated with human papillomavirus (HPV) infections, though they may also arise from other viral or non-viral factors. While papillomas are typically non-cancerous, they can cause significant discomfort and in some cases lead to malignant transformation. They occur in various anatomical regions - including the skin, oral cavity, respiratory tract, and genitals - making effective diagnosis and treatment critical.
Download Full PDF Sample Copy of Market…
Pancreatic Ductal Carcinoma Market to Hit USD 11.2 Billion by 2034
Pancreatic ductal carcinoma (PDAC) is the most common type of pancreatic cancer, accounting for more than 90% of cases, and is one of the deadliest malignancies worldwide. Often diagnosed at advanced stages due to nonspecific symptoms, PDAC has a poor prognosis and remains a major clinical challenge. Despite its aggressive nature, advances in early diagnostics, immunotherapy, precision medicine, and combination therapies are beginning to reshape the treatment landscape.
Download Full PDF…
Atopic Dermatitis Market is expected to double by 2034, reaching USD 13.1 billio …
Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin disorder that affects millions worldwide, characterized by intense itching, redness, and recurrent flare-ups. While the disease manifests at any age, it is most common among children, often carrying a significant burden into adulthood. The psychosocial and economic impacts of AD are substantial, making patient pool analysis critical for understanding epidemiology, treatment adoption, and future opportunities.
Download Full PDF Sample…
More Releases for NSAID
NSAID API Market, Strategic Developments, Demand Surge in Chronic Pain Treatment …
Overview of the NSAID API Market
The global NSAID (Nonsteroidal Anti-inflammatory Drug) Active Pharmaceutical Ingredients (API) market is witnessing significant momentum, primarily driven by increasing incidences of chronic pain, arthritis, and inflammatory diseases worldwide. These APIs serve as the core components in formulating a wide range of prescription and over-the-counter analgesic medications. As the burden of non-communicable diseases rises globally, especially among the aging population, the demand for NSAID-based treatments has…
NSAID Ophthalmic Drugs Latest Market Analysis Report 2025
On Mar 12, 2025, Global Info Research released a research report titled "Global NSAID Ophthalmic Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031". This report provides detailed data analysis of the NSAID Ophthalmic Drugs market from 2020 to 2031. Including the market size and development trends of NSAID Ophthalmic Drugs Market, it analyzes market size indicators such as sales, sales volume, average price and CAGR, it…
Global NSAID Ophthalmic Drugs Market Analysis By Major Manufacturers and Competi …
Globally, NSAID Ophthalmic Drugs key manufacturers include AbbVie, Bausch Health, Bayer, Dossa Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, Pfizer and Sun Pharmaceutical Industries, etc. AbbVie, Bausch Health, Bayer are top 3 players and held % sales share in total in 2022
Global NSAID Ophthalmic Drugs Market: Driven factors and Restrictions factors
The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of…
Non-steroidal Anti-inflammatory Drugs (NSAID) Market Will Escalate Rapidly In Th …
Global Non-steroidal Anti-inflammatory Drugs (NSAID) Market 2022 research report initially provides a basic overview of the Market that covers definition, applications and manufacturing technology, post which the report explores into the international players in the market.
Request sample pages of this research study at -
https://www.theinsightpartners.com/sample/TIPRE00004421/?utm_source=OpenPR&utm_medium=10366
The non-steroidal anti-inflammatory drugs are a type of pain reliever that help to reduce inflammation and lower fevers. The NSAIDs are the most prescribed medications, which are…
Global NSAID API Market Size,Depth Research Report 2022-2028|Novartis, Pfizer, B …
Global Market For NSAID API Estimated At US$ Million In The Year 2022, Is Projected To Reach A Revised Size Of US$ Million By 2028, Growing At A CAGR Of % During The Forecast Period 2022-2028.
Los Angeles, United States October 2022,- The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global NSAID API market. It sheds light on how the…
IoT (Internet Of Medical Things) To Be The Buzzword For NSAID API Market
An Active Pharmaceutical Ingredient (API) is a bulk drug used as an ingredient in a dosage form. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that group together drugs that provide analgesic (analgesic) and antipyretic (reducing fever) effects and, at high doses, anti-inflammatory effects.
Get Sample Copy of This Report @ https://www.persistencemarketresearch.com/samples/17038
The term nonsteroidal distinguishes these drugs from steroids, which have similar eicosanoid inhibitory, anti-inflammatory properties, among a wide…
